BTIG, a leading investment firm, has revealed its top healthcare picks for the second half of 2023. Among the selected companies are Acumen, BridgeBio, and Arcus [1].
Acumen, a clinical-stage biopharmaceutical company, is dedicated to developing treatments for rare and orphan diseases. With two lead programs in Phase II clinical trials and a promising preclinical program. Acumen shows great potential in addressing unmet medical needs [1].
BridgeBio, another standout company, specializes in discovering, developing, and commercializing therapies for genetic diseases. With an impressive pipeline boasting over 20 drug candidates, BridgeBio is positioning itself for future growth and innovation.
Arcus, the third company on BTIG’s Top Healthcare Picks 2023, focuses on the development of antibodies to combat serious diseases. With two lead programs already in Phase II clinical trials, Arcus is making strides toward groundbreaking treatments.
BTIG is optimistic about the future of these three companies. Acumen projects to complete its Phase II clinical trials and commence Phase III trials in 2023, showcasing significant progress.
Similarly, BridgeBio expects to submit several Investigational New Drug (IND) applications and initiate Phase I clinical trials in 2023, demonstrating its commitment to advancing therapies.
Arcus expects to reach key milestones, completing Phase II clinical trials and commencing Phase III trials in 2023.
BTIG has set ambitious 12-month price targets for these healthcare contenders. Acumen expects to reach $30 per share, while BridgeBio aims for $48 per share and Arcus targets $32 per share.
These BTIG’s Top Healthcare Picks 2023 highlight the potential growth and impact these companies can have on the industry. As investors and stakeholders closely monitor their progress, the second half of 2023 promises to be a period of significant advancement and value creation in the healthcare sector.